Folate-mediated solid–liquid lipid nanoparticles for paclitaxel-coated poly(ethylene glycol)

References

• Horwitz SB. (1992). Mechanism of action of taxol. Trends. Pharmacol Sci, 13:134–6.
   PubMed Web of Science ®Google Scholar
• Spencer CM, Faulds D. (1994). Paclitaxel. Drugs, 48:794–847.
   PubMed Web of Science ®Google Scholar
• Gregory RE, DeLisa AF. (1993). Paclitaxel: A new antineoplastic agent for refractory ovarian cancer. Clin Pharm, 12:401–15.
   PubMedGoogle Scholar
• Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV. (2003). Paclitaxel resistance: Molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets, 3:1–19.
   PubMed Web of Science ®Google Scholar
• Lee J, Lee SC, Acharya G, Chang CJ, Park K. (2003). Hydrotropic solubilization of paclitaxel: Analysis of chemical structures for hydrotropic property. Pharm Res, 20:1022–30.
   PubMed Web of Science ®Google Scholar
• Henningsson A, Karlsson MO, Vigano L. (2001). Mechanism based pharmacokinetic model for paclitaxel. J Clin Oncol, 19:4065–73.
   PubMed Web of Science ®Google Scholar
• Szebeni J, Muggia FM, Alving CR. (1998). Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: An in vitro study. J Natl Cancer Inst, 90:300–6.
   PubMed Web of Science ®Google Scholar
• Song D, Hsu LF, Au JLS. (1996). Binding of paclitaxel to plastic glass container and protein under in vitro conditions. J Pharm Sci, 85:29–31.
   PubMed Web of Science ®Google Scholar
• Paradis R, Page M. (1998). New active paclitaxel amino acids derivatives with improved water solubility. Anticancer Res, 18(2711–6):
   PubMedGoogle Scholar
• Constantinides PP, Tustian A, Kessler DR. (2004). Tocol emulsion for drug solubilization and parenteral delivery. Adv Drug Deliv Rev, 56:1243–55.
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, . (2005). Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol, 23:7794–803.
   PubMed Web of Science ®Google Scholar
• Gradishar WJ. (2006). Albumin-bound paclitaxel: A next-generation taxane. Expert Opin Pharmacother, 7(8):1041–53.
   PubMed Web of Science ®Google Scholar
• Müller RH, Mäder K, Gohla S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the art. Eur J Pharm Biopharm, 50:161–77.
   PubMed Web of Science ®Google Scholar
• Chen DB, Yang TZ, Lu WL, Zhang Q. (2001). In vitro and in vivo study of two types of long-circulating solid lipid nanoparticless containing paclitaxel. Chem Pharm Bull, 49:1444–7.
   PubMed Web of Science ®Google Scholar
• Wissing SA, Kayser O, Müller RH. (2004). Solid lipid nanoparticless for parenteral drug delivery. Adv Drug Deliv Rev, 56:1257–72.
   PubMed Web of Science ®Google Scholar
• Jores K, Mehnert W, Drechsler M, Bunjes H, Johann C, Mäder K. (2004). Investigations on the structure of solid lipid nanoparticless (SLN) and oil-loaded solid lipid nanoparticless by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy. J Control Release, 95:217–27.
   PubMed Web of Science ®Google Scholar
• Torchilin VP, Trubetskoy VS. (1995). Which polymers can make nanoparticulate drug carriers long-circulating?. Adv Drug Deliv Rev, 16:141–55.
   Web of Science ®Google Scholar
• Laginha K, Mumbengegwi D, Allen T. (2005). Liposomes targeted via two different antibodies: Assay, B-cell binding and cytotoxicity. Biochim Biophys Acta, 1711:25–32.
   PubMed Web of Science ®Google Scholar
• Campbell IG, Jones TA, Foulkes WD, Trowsdale J. (1991). Folate-binding protein is a marker for ovarian cancer. Cancer Res, 51:5329–38.
   PubMed Web of Science ®Google Scholar
• Garin-Chesa P, Campbell I, Saigo PE, Lewis JL, Old LJ, Rettig WJ. (1993). Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am J Pathol, 142:557–67.
   PubMed Web of Science ®Google Scholar
• Ross JF, Chaudhuri PK, Ratnam M. (1994). Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Cancer, 73(2432–43):
   Google Scholar
• Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP. (2005). Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem, 338:284–93.
   PubMed Web of Science ®Google Scholar
• Leamon CP, Low PS. (1994). Selective targeting of malignant cells with cytotoxin-folate conjugates. J Drug Target, 2:101–12.
   PubMed Web of Science ®Google Scholar
• Lee RJ, Low PS. (1994). Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J Biol Chem, 269:3198–204.
   PubMed Web of Science ®Google Scholar
• Lee RJ, Low PS. (1995). Folate-mediated tumor cell targeting of liposome entrapped doxorubicin in vitro. Biochim Biophys Acta, 1233:134–44.
   PubMed Web of Science ®Google Scholar
• Wang S, Lee RJ, Mathias CJ, Green MA, Low PS. (1996). Synthesis, purification, and tumor cell uptake of 67Ga-deferoxamine-folate, a potential radiopharmaceutical for tumor imaging. Bioconjug Chem, 7(1):56–62.
   PubMed Web of Science ®Google Scholar
• Li S, Deshmukh HM, Huang L. (1998). Folate-mediated targeting of antisense oligodeoxynucleotides to ovarian cancer cells. Pharm Res, 15:1540–5.
   PubMed Web of Science ®Google Scholar
• Shinoda T, Takagi A, Maeda A, Kagatani S, Konno Y, Hashida M. (1998). In vivo fate of folate-BSA in non-tumor- and tumorbearing mice. J Pharm Sci, 87:1521–6.
   PubMed Web of Science ®Google Scholar
• Zhou W, Yuan X, Wilson A, Yang L, Mokotoff M, Pitt B, . (2002). Efficient intracellular delivery of oligonucleotides formulated in folate receptor-targeted lipid vesicles. Bioconjug Chem, 13:1220–5.
   PubMed Web of Science ®Google Scholar
• Ke CY, Mathias CJ, Green MA. (2003). The folate receptor as a molecular target for tumor-selective radionuclide delivery. Nucl Med Biol, 30:811–7.
   PubMed Web of Science ®Google Scholar
• Carlsson G, Gullberg B, Hafstrom L. (1983). Estimation of liver tumor volume using different formulas—an experimental study in rats. J Cancer Res Clin Oncol, 105:20–3.
   PubMed Web of Science ®Google Scholar
• Jung KO, Park SY, Park KY. (2006). Longer aging time increases the anticancer and antimetastatic properties of doenjang. Nutrition, 22:539–45.
   Google Scholar
• Liu M, Xu W, Xu LJ, Zhong GR, Chen SL. (2005). Synthesis and biological evaluation of diethylenetriamine pentaacetic acid-polyethylene glycol-folate: A new folate-derived, 99mTc-based radiopharmaceutical. Bioconjug Chem, 16:1126–32.
   PubMed Web of Science ®Google Scholar
• Sahoo SK, Ma W, Labhasetwar V. (2004). Efficacy of transferrinconjugated paclitaxel-loaded nanoparticless in a murine model of prostate cancer. Int J Cancer, 112:335–40.
   PubMed Web of Science ®Google Scholar
• Yang T, Choi MK, Cui FD, Kim JS, Chung SJ, Shim CK, . (2007). Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. J Control Release, 120:169–77.
   PubMed Web of Science ®Google Scholar
• Lawrence JM, Petitti DB, Watkins M, Umekubo MA. (1999). Trends in serum folate after food fortification. Lancet, 354:915–6.
   PubMed Web of Science ®Google Scholar
• Yoo HS, Park TG. (2004). Folate receptor targeted biodegradable polymeric doxorubicin micelles. J Control Release, 96:273–83.
   PubMed Web of Science ®Google Scholar
• Zhang LK. (2005). Study on drug delivery system of folate-receptor-mediated mitoxantrone albumin nanoparticless targeting ovarian cancer cell. In: Doctoral dissertation, , China: Sichuan University.
   Google Scholar